FDA Advisory Panel Recommends Easier Access to Popular Peptides

A federal advisory panel to the Food and Drug Administration (FDA) has narrowly recommended making it easier for patients to access certain peptides. In a series of votes held this week, the committee advised the agency to remove current restrictions that prevent specialized pharmacies from producing these substances. While the panel’s decision is not a final law, it is a significant step that could change how these products are sold and used across the United States.

Peptides are small chains of amino acids that act as signaling molecules in the human body. While some peptides are used in approved, life-saving medications like insulin or treatments for diabetes and weight loss, the substances currently under review—such as BPC-157 and KPV—have not undergone the same large-scale testing required for standard drug approval. Despite this, they have become very popular among wellness influencers and celebrities, who often promote them for building muscle, healing injuries, and increasing energy.

According to The Guardian Health, the panel voted 8-6 in favor of adding these substances to the FDA’s list of products that pharmacies can create. This vote occurred during a two-day meeting where experts considered whether to lift restrictions put in place during the Biden administration. NPR Health reports that the FDA’s own scientists strongly advised against this move, noting that there is very little data to show that these chemicals are safe or effective for medical use. Government experts expressed concern that these products could cause serious health issues, including infections or allergic reactions.

The recent votes highlight a deep divide among experts regarding the best way to protect public health. Some members of the committee argued that because many people are already using these substances, it is safer to allow them to be produced by licensed pharmacies rather than forcing patients to buy them from unregulated online sources. Dr. Jessica Duncan, a medical officer at the telehealth company IVIM Health, told the panel that many patients are already using these drugs from the "worst possible places." She argued that the real question is whether people should use them under the care of a doctor or completely on their own.

However, other experts remain highly critical of the decision. Dr. Elizabeth Rebello of the University of Texas MD Anderson Center warned that the panel’s recommendation seems to be a response to market demand rather than solid scientific evidence. Similarly, Todd Durham, a consumer representative on the committee, voted against the proposal. He noted that there is a lack of evidence for the effectiveness of these substances and expressed worry about the potential for long-term harm to patients. MedPage Today reported that these substances are often sold in "stacks"—combinations of different products—which further complicates safety concerns.

Much of the controversy stems from the recent makeup of the advisory panel. According to The Guardian Health and MedPage Today, the committee was recently reorganized by Health Secretary Robert F. Kennedy Jr., who has publicly stated that he is a fan of peptides. Several new members added to the panel have professional ties to the peptide industry, including doctors and pharmacists who sell these products in their own clinics. This has led to public criticism regarding potential conflicts of interest, as some members stand to benefit financially if the restrictions are removed.

As the situation develops, the focus now shifts to the FDA. While the agency is not legally required to follow the committee’s advice, it usually does. If the FDA chooses to follow the panel’s recommendation, it would allow pharmacies to legally produce and sell these peptides. This could lead to a significant increase in marketing by telehealth companies, which are eager to sell these products for wellness and cosmetic purposes.

For now, the debate continues. Supporters of the move argue that it empowers patients and doctors to make their own health decisions, while critics maintain that the "wild west" of unproven drugs poses an unacceptable risk to the public. As the FDA considers its next steps, the medical community remains divided on whether this decision will lead to safer access or simply encourage the use of products that have not yet been proven to work.